Arrowhead Research Corporation, a biopharmaceutical company currently developing targeted RNAi therapeutics, recently announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation for its experimental ARC-AAT therapy. ARC-AAT is the company’s RNAi-based therapeutic ... Read more